A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy (DMD)

Inclusion Criteria:

- Has a genetic diagnosis of DMD and an out-of-frame deletion mutation of the DMD gene
amenable to exon 51 skipping treatment

- Has been on a stable dose of oral corticosteroids for at least 12 weeks prior to study
drug administration with continued dosing of oral corticosteroids while participating
in the study*, or has not received corticosteroids for at least 12 weeks prior to
study drug administration and will not initiate dosing of oral corticosteroids while
participating in the study

Exclusion Criteria:

- Has a left ventricular ejection fraction (LVEF) less than (<) 40 percent (%) based on
an echocardiogram (ECHO) performed within 3 months prior to Screening or at the
Screening visit

- Has a QT interval corrected with Fridericia's method (QTcF) >= 450 millisecond (msec)
on the Screening electrocardiogram (ECG)

- Initiation or change of dosing (except for modifications to accommodate changes in
weight) within 12 weeks prior to Screening and while participating in the study for
any of the following: angiotensin-converting enzyme (ACE) inhibitors,
angiotensin-receptor blocking agents (ARBs), beta-blockers, or potassium

- Requires antiarrhythmic and/or diuretic therapy for heart failure

- Forced vital capacity (FVC) <40% of predicted value within 3 months of Screening or at
the Screening visit

- Known kidney disease or had an acute kidney injury within 6 months prior to Screening

- Treatment with eteplirsen or drisapersen within 6 months prior to Screening, or any
experimental gene therapy for the treatment of DMD at any time

- Use of any herbal medication/supplement containing aristolochic acid

Other inclusion/exclusion criteria apply.

*The dose of steroids must remain constant except for modifications to accommodate changes
in weight.